First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study

被引：2

作者：

Schneeweiss, Andreas ^{[1
]}

Forster, Frank ^{[2
,3
]}

Tesch, Hans ^{[4
]}

Aktas, Bahriye ^{[5
]}

Gluz, Oleg ^{[6
]}

Geberth, Matthias ^{[7
]}

Hertz-Eichenrode, Martin M. ^{[8
]}

Schonegg, Winfried ^{[9
]}

Schumacher, Claudia ^{[10
]}

Kutscheidt, Andreas ^{[11
]}

Kiewitz, Claudia ^{[12
]}

Klawitter, Sandra ^{[12
]}

Schmidt, Marcus ^{[13
]}

机构：

[1] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany

[2] Outpatient Dept Gynecol Oncol Chemnitz, Chemnitz, Germany

[3] Univ Appl Sci Zwickau, Chemnitz, Germany

[4] Bethanien Hosp, Ctr Hematol & Med Oncol, Frankfurt, Germany

[5] Univ Duisburg Essen, Dept Gynecol & Obstet, Essen, Germany

[6] West German Study Grp, Monchengladbach, Germany

[7] Dept Gynecooncol Mannheim, Mannheim, Germany

[8] Praxis Hertz Eichenrode N Kolloch, Remscheid, Germany

[9] Praxis Winfried Schonegg, Berlin, Germany

[10] St Elizabeth Hosp, Breast Ctr Koln Hohenlind, Cologne, Germany

[11] WiSP Res Inst, Langenfeld, Germany

[12] Roche Pharma AG, Grenzach, Germany

[13] Univ Hosp Mainz, Dept Obstet & Gynecol, Mainz, Germany

来源：

ANTICANCER RESEARCH | 2016年 / 36卷 / 03期

关键词：

Anti-angiogenic; bevacizumab; first-line; metastatic breast cancer; vascular endothelial growth factor; PHASE-III; PACLITAXEL;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: The German ML21165 study evaluated bevacizumab-containing therapy for metastatic breast cancer (mBC) in routine oncology practice. Patients and Methods: Patients received bevacizumab with chemotherapy until disease progression, unacceptable toxicity or consent withdrawal. Pre-specified end-points were safety and efficacy [response rate, progression-free survival (PFS) and overall survival (OS)]. Results: Between May 2007 and September 2009, 865 patients received first-line bevacizumab plus paclitaxel for mBC, of whom 16% were aged >= 70 years and 9% had ECOG performance status of 2 or more. At data cut-off (median of 15.9 months' follow-up), the median PFS was 9.6 months [95% confidence interval (CI)=9.0-10.4 months] and the median OS was 21.6 months (95% CI=19.4-23.5 months). The most common non-haematological adverse drug reactions of grade 3 or more were pain (9%), hypertension (5%), sensory neuropathy (3%) and proteinuria (3%). Prolonged bevacizumab was well-tolerated. Conclusion: The efficacy and safety of first-line bevacizumab-paclitaxel in routine oncology practice is consistent with results from randomized trials.

引用

页码：967 / 974

页数：8

共 50 条

[1] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Salvador, J.
Manso, L.
de la Haba, J.
Jaen, A.
Ciruelos, E.
de Villena, M. C.
Gil, M.
Murias, A.
Galan, A.
Jara, C.
Bayo, J.
Baena, J. M.
Casal, J.
Mel, J. R.
Blancas, I.
Sanchez Rvira, P.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02): : 160 - 166
[2] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
J. Salvador
L. Manso
J. de la Haba
A. Jaen
E. Ciruelos
M. C. de Villena
M. Gil
A. Murias
A. Galan
C. Jara
J. Bayo
J. M. Baena
J. Casal
J. R. Mel
I. Blancas
P. Sanchez Rvira
Clinical and Translational Oncology, 2015, 17 : 160 - 166
[3] Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Lobo, Christopher
Lopes, Gilberto
Baez, Odalys
Castrellon, Aurelio
Ferrell, Annapoorna
Higgins, Connie
Hurley, Erin
Hurley, Judith
Reis, Isildinha
Richman, Stephen
Seo, Pearl
Silva, Orlando
Slingerland, Joyce
Tukia, Keleni
Welsh, Catherine
Glueck, Stefan
BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (02) : 427 - 435
[4] Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Christopher Lobo
Gilberto Lopes
Odalys Baez
Aurelio Castrellon
Annapoorna Ferrell
Connie Higgins
Erin Hurley
Judith Hurley
Isildinha Reis
Stephen Richman
Pearl Seo
Orlando Silva
Joyce Slingerland
Keleni Tukia
Catherine Welsh
Stefan Glück
Breast Cancer Research and Treatment, 2010, 123 : 427 - 435
[5] Final results of a phase II study of combination with nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy in patients with HER2-negative metastatic breast cancer
Glueck, S.
Lobo, C.
Lopes, G.
Castrellon, A.
Hurley, J.
Reis, I.
Richman, S.
Silva, O.
Slingerland, J.
Welsh, C.
EJC SUPPLEMENTS, 2010, 8 (03): : 196 - 196
[6] First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study
Mueller, Volkmar
Ruhnke, Markus
Hoffmann, Oliver
Grafe, Andrea
Tome, Oliver
Fett, Werner
Bruch, Harald-Robert
Sommer-Joos, Ann-Katrin
Schneeweiss, Andreas
BREAST, 2021, 60 : 70 - 77
[7] Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
Vrdoljak, E.
Marschner, N.
Zielinski, C.
Gligorov, J.
Cortes, J.
Puglisi, F.
Aapro, M.
Fallowfield, L.
Fontana, A.
Inbar, M.
Kahan, Z.
Welt, A.
Levy, C.
Brain, E.
Pivot, X.
Putzu, C.
Gonzalez Martin, A.
de Ducla, S.
Easton, V.
von Minckwitz, G.
ANNALS OF ONCOLOGY, 2016, 27 (11) : 2046 - 2052
[8] First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study
Dieras, Veronique
Pop, Simona
Berger, Frederique
Dujaric, Marie-Eglantine
Beuzeboc, Philippe
Escalup, Laurence
Bidard, Francois Clement
Cottu, Paul Henri
Le Tourneau, Christophe
Piperno-Neumann, Sophie
Laurence, Valerie
Robain, Mathieu
Asselain, Bernard
Pierga, Jean-Yves
ANTICANCER RESEARCH, 2017, 37 (03) : 1403 - 1407
[9] Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer
Tiainen, Leena
Tanner, Minna
Lahdenpera, Outi
Vihinen, Pia
Jukkola, Arja
Karihtala, Peeter
Paunu, Niina
Huttunen, Teppo
Kellokumpu-Lehtinen, Pirkko-Liisa
ANTICANCER RESEARCH, 2016, 36 (12) : 6431 - 6438
[10] Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients
Fabi, A.
Russillo, M.
Metro, G.
Papaldo, P.
Nistico, C.
Ferretti, G.
Cuppone, F.
D'Auria, G.
Giannarelli, D.
Cognetti, F.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 →